Document Detail


Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.
MedLine Citation:
PMID:  20002471     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with features of the metabolic syndrome (MetS) and may be an expression of the syndrome within the liver. Using screening data from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study (n = 42 149), we examined whether alanine aminotransferase (ALT), a biomarker for NAFLD, clustered with features of MetS and whether the clusters differed across global geographic regions. METHODS: Exploratory factor analysis using principle components analysis was applied to data drawn from the NAVIGATOR screening population (n = 41 111). Demographic data, anthropomorphic measurements and blood pressure (BP) collected during the screening visit, as well as blood samples analysed for ALT, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, and fasting and 2-h glucose measures after an oral glucose tolerance test were used for our analysis. RESULTS: Two factors, interpreted as lipid (Factor 1), and BP/obesity (Factor 2) were identified, explaining approximately 50% of the variance in the overall population. Similar patterns of aggregation were reproducible across all geographic regions except Asia, where fasting glucose loaded more consistently on Factor 1. ALT loaded with mean arterial pressure, fasting glucose and waist circumference except in Asia, where it loaded only with mean arterial pressure and waist circumference. CONCLUSIONS: ALT aggregated with components of MetS, and the pattern of aggregation of ALT with other features of MetS was similar across regions except Asia, possibly indicating a different pathophysiology for NAFLD in Asia. Predictive models of NAFLD may need to be adjusted for regional and ethnic differences.
Authors:
M A Bethel; P Deedwania; N S Levitt; O Schmitz; A Huntsman-Labed; R M Califf; S M Haffner; P Diem;
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetic medicine : a journal of the British Diabetic Association     Volume:  26     ISSN:  1464-5491     ISO Abbreviation:  Diabet. Med.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-16     Completed Date:  2010-06-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8500858     Medline TA:  Diabet Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1204-11     Citation Subset:  IM    
Affiliation:
Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. angelyn.bethel@dtu.ox.ac.uk
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00097786
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Alanine Transaminase / blood*,  diagnostic use
Biological Markers
Blood Pressure
Cholesterol / blood
Factor Analysis, Statistical
Fatty Liver / complications,  metabolism
Female
Glucose Intolerance / complications
Glucose Tolerance Test
Humans
Lipoproteins / blood
Male
Metabolic Syndrome X / blood*,  physiopathology*
Middle Aged
Obesity / physiopathology
Predictive Value of Tests
Triglycerides / blood
World Health
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Lipoproteins; 0/Triglycerides; 57-88-5/Cholesterol; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of proposed oral disposition index measures in relation to the actual disposition index.
Next Document:  Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifesty...